Aurion Biotech, a clinical-stage biotech company aiming to restore vision to millions of patients with regenerative therapies, announced on Wednesday that AURN001, an allogeneic cell therapy for corneal edema, has secured both Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA).
AURN001 is the first therapy of its kind to achieve this dual designation for the treatment of corneal edema secondary to corneal endothelial disease.
BTD expedites development for treatments with promising clinical data, while RMAT recognizes the potential of regenerative therapies for unmet medical needs. These designations aim to accelerate AURN001's path to market, leveraging positive results from ongoing Phase 1/2 trials.
AURN001 has already received regulatory approval in Japan.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval